These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1348824)

  • 21. Complete remission in multiple myeloma.
    Lancet; 1990 Jan; 335(8680):52-3. PubMed ID: 1967357
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of multiple myeloma in elderly people: long-term results in 178 patients.
    Bladé J; Muñoz M; Fontanillas M; San Miguel J; Alcalá A; Maldonado J; Besses C; Moro MJ; García-Conde J; Rozman C; Montserrat E; Estapé J
    Age Ageing; 1996 Sep; 25(5):357-61. PubMed ID: 8921139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Possibility of using interferon in the treatment of multiple myeloma].
    Piatkowska-Jakubas B; Skotnicki AB; Blicharski J
    Przegl Lek; 1988; 45(10):747-50. PubMed ID: 3072590
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma.
    Cohen HJ; Silberman HR; Larsen WE; Johnson L; Bartolucci AA; Durant JR
    Blood; 1979 Oct; 54(4):824-36. PubMed ID: 476303
    [No Abstract]   [Full Text] [Related]  

  • 25. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
    Suvannasankha A; Fausel C; Juliar BE; Yiannoutsos CT; Fisher WB; Ansari RH; Wood LL; Smith GG; Cripe LD; Abonour R
    Oncologist; 2007 Jan; 12(1):99-106. PubMed ID: 17227904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
    Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Complications and managements in treatment of melphalan, prednisone and new agents].
    Ishida T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():649-52. PubMed ID: 25831841
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of multiple myeloma: an Argentine Group for the Treatment of Acute Leukemia Study.
    Dhingra K
    J Clin Oncol; 1988 Nov; 6(11):1784-5. PubMed ID: 3054007
    [No Abstract]   [Full Text] [Related]  

  • 29. [Bortezomib-based triple combinations (VCD, PAD) for untreated patients with multiple myeloma].
    Izumi T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():646-8. PubMed ID: 25831840
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pneumonia caused by Salmonella in a patient with myeloma].
    Fernández P; Roldán V; García MC; Gil MT; Rivas C
    Sangre (Barc); 1995 Jun; 40(3):234-5. PubMed ID: 7570286
    [No Abstract]   [Full Text] [Related]  

  • 31. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acute ischemia and heart failure during cyclic chemotherapy in a patient with plasmocytic myeloma].
    Drzewoski J; Olszańska-Skorek T; Urbańska-Ryś H; Kończalik P; Krykowski E
    Pol Tyg Lek; 1990 Dec 17-31; 45(51-52):1056-8. PubMed ID: 2098746
    [No Abstract]   [Full Text] [Related]  

  • 33. Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
    Brugnatelli S; Riccardi A; Ucci G; Mora O; Barbarano L; Piva N; Piccinini L; Bergonzi C; De Paoli A; Di Stasi M; Rinaldi E; Trotti G; Petrini M; Ascari E
    Br J Cancer; 1996 Mar; 73(6):794-7. PubMed ID: 8611382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rate of M-component changes and clinical course of 23 responsive myeloma patients.
    Riccardi A; Montecucco C; Merlini G; Cremonini N; Danova M; Ascari E
    Haematologica; 1984; 69(3):305-14. PubMed ID: 6432642
    [No Abstract]   [Full Text] [Related]  

  • 35. An aggressive high dose cyclophosphamide and prednisone regimen for advanced multiple myeloma.
    Lenhard RE; Daniels MJ; Oken MM; Glick JH; Ettinger DS; Kalish L; O'Connell MJ
    Leuk Lymphoma; 1994 May; 13(5-6):485-9. PubMed ID: 8069193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Indications for chemotherapy in multiple myeloma].
    Heyll A; Aul C
    Dtsch Med Wochenschr; 1996 May; 121(20):675. PubMed ID: 8635404
    [No Abstract]   [Full Text] [Related]  

  • 37. Low dose oral idarubicin in combination with cyclophosphamide and dexamethasone (CID) for management of melphalan-prednisolone (MP) resistant myeloma.
    Kashyap S; Ganguly K; Bardhan G; Majumdar G
    Leuk Lymphoma; 1999 Apr; 33(3-4):407-8. PubMed ID: 10221525
    [No Abstract]   [Full Text] [Related]  

  • 38. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
    Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
    Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
    Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; Anglin P; Chen C; Kukreti V; Mikhael JR; Trudel S
    Br J Haematol; 2015 Jan; 168(1):46-54. PubMed ID: 25146584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.